Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
-
Published:2024-07
Issue:
Volume:48
Page:101122
-
ISSN:2666-6065
-
Container-title:The Lancet Regional Health - Western Pacific
-
language:en
-
Short-container-title:The Lancet Regional Health - Western Pacific
Author:
Shi YuankaiORCID, Chen Gongyan, Wang Xiang, Liu Yunpeng, Wu Lin, Hao Yanrong, Liu Chunling, Zhu Shuyang, Zhang Xiaodong, Li Yuping, Liu Jiwei, Cao Lejie, Cheng Ying, Zhao Hui, Zhang Shucai, Zang Aimin, Cui Jiuwei, Feng Jian, Yang Nong, Hu Jie, Liu Fei, Jiang Yong, Ge Nan
Reference33 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021 2. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014 3. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009 4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010 5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
|
|